The Patient's Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression.
glutamatergic system
mood disorders
patient experience
personalized medicine
psychopharmacology
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
22 Oct 2023
22 Oct 2023
Historique:
received:
18
09
2023
revised:
16
10
2023
accepted:
19
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients' perceptions about the helpfulness of treatments. We aimed to verify the effect of ESK-NS from patients' view in 25 TRD patients (56% males, 55.1 ± 10.9 years) treated with ESK-NS (mean dose: 78.4 ± 11.43 mg) for three months and evaluated at different time-points through clinician-rated and self-administered scales, assessing changes in depression, anhedonia, sleep, cognition, suicidality, and anxiety. We observed an overall early improvement that lasted over time (endpoint total score reduction in Montgomery-Åsberg Depression Rating Scale,
Identifiants
pubmed: 37891860
pii: brainsci13101494
doi: 10.3390/brainsci13101494
pmc: PMC10604956
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neuropsychiatr Dis Treat. 2021 Jul 15;17:2347-2357
pubmed: 34290505
Eur Neuropsychopharmacol. 2023 Sep;74:15-21
pubmed: 37148637
JAMA Psychiatry. 2020 Aug 1;77(8):830-841
pubmed: 32432716
J Affect Disord. 2022 Dec 15;319:646-654
pubmed: 36167246
Mol Psychiatry. 2022 Mar;27(3):1286-1299
pubmed: 34907394
Psychosomatics. 1971 Nov-Dec;12(6):371-9
pubmed: 5172928
Br J Med Psychol. 1959;32(1):50-5
pubmed: 13638508
Br J Clin Psychol. 2022 Jun;61(2):255-280
pubmed: 34625993
Depress Anxiety. 2020 Feb;37(2):134-145
pubmed: 31638723
Mol Psychiatry. 2021 Jul;26(7):3292-3301
pubmed: 32929215
Am J Geriatr Psychiatry. 2023 Jul 8;:
pubmed: 37479669
Psychopharmacology (Berl). 2023 Jul;240(7):1547-1560
pubmed: 37222753
Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):401-409
pubmed: 37424409
Ther Adv Chronic Dis. 2016 May;7(3):153-9
pubmed: 27347362
J Psychiatr Res. 2023 Feb;158:209-215
pubmed: 36603315
Depress Anxiety. 2009;26(1):83-97
pubmed: 18833573
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110:110289
pubmed: 33631251
Psychol Med. 2022 Feb;52(3):419-432
pubmed: 34991768
J Clin Psychiatry. 2021 Mar 16;82(2):
pubmed: 33989464
J Pers Med. 2023 Jun 29;13(7):
pubmed: 37511694
Qual Life Res. 2023 Nov;32(11):3053-3061
pubmed: 37439961
BMC Psychiatry. 2023 Aug 11;23(1):587
pubmed: 37568081
World Psychiatry. 2023 Oct;22(3):352-365
pubmed: 37713566
BMC Psychiatry. 2023 Jul 28;23(1):548
pubmed: 37507656
Int J Neuropsychopharmacol. 2022 Apr 19;25(4):269-279
pubmed: 35022754
Neuropsychopharmacology. 2017 Jan;42(1):1-4
pubmed: 27909328
World Psychiatry. 2020 Oct;19(3):269-293
pubmed: 32931110
J Affect Disord. 2021 Oct 1;293:285-294
pubmed: 34225208
Eur Neuropsychopharmacol. 2020 Mar;32:94-103
pubmed: 31973999
Neuropharmacology. 2023 Feb 1;223:109299
pubmed: 36336068
Psychol Bull. 2020 Dec;146(12):1117-1145
pubmed: 33119344
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Adv Exp Med Biol. 2023;1411:487-512
pubmed: 36949323
Compr Psychiatry. 2011 Jan-Feb;52(1):26-32
pubmed: 21220062
Am J Psychiatry. 2021 May 1;178(5):383-399
pubmed: 33726522
Brain Sci. 2023 Aug 21;13(8):
pubmed: 37626579
Psychopharmacology (Berl). 2022 Jul;239(7):2011-2039
pubmed: 35292831
Neurosci Biobehav Rev. 2023 Sep;152:105307
pubmed: 37419230
Neurosci Biobehav Rev. 2023 Feb;145:105000
pubmed: 36529312
Neurol Sci. 2022 May;43(5):3053-3063
pubmed: 34989910
Int Clin Psychopharmacol. 2022 Jan 1;37(1):21-24
pubmed: 34825899
Rev Assoc Med Bras (1992). 2023 May 15;69(4):e2023D694
pubmed: 37194806
Int J Neuropsychopharmacol. 2021 Oct 23;24(10):808-831
pubmed: 34170315
J Psychiatr Pract. 2023 Jul 01;29(4):325-332
pubmed: 37449831
Clin Neuropsychiatry. 2023 Jun;20(3):173-182
pubmed: 37522111
Int Clin Psychopharmacol. 2022 May 1;37(3):79-81
pubmed: 35357329
Int Clin Psychopharmacol. 2023 Sep 1;38(5):297-328
pubmed: 37381161
Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):429-446
pubmed: 37424412
Eur Psychiatry. 2000 May;15(3):160-72
pubmed: 10881213
Lancet Psychiatry. 2021 Jan;8(1):14-15
pubmed: 33341160
Eur Arch Psychiatry Clin Neurosci. 2023 May 8;:
pubmed: 37154920
Pharmaceuticals (Basel). 2023 Apr 21;16(4):
pubmed: 37111391
EClinicalMedicine. 2023 Jul 13;61:102084
pubmed: 37528846
Eur J Neurosci. 2021 Jan;53(1):151-171
pubmed: 32150310
Neuropsychiatr Dis Treat. 2023 Mar 14;19:587-599
pubmed: 36942150
Int J Mol Sci. 2021 Aug 28;22(17):
pubmed: 34502248
Neurol Int. 2023 Jan 16;15(1):100-120
pubmed: 36648973
Parkinsonism Relat Disord. 2009 Sep;15(8):576-81
pubmed: 19362509
J Affect Disord. 2021 Jan 1;278:515-518
pubmed: 33017679
Bipolar Disord. 2023 May;25(3):233-244
pubmed: 36636839
Depress Anxiety. 2018 Jul;35(7):668-673
pubmed: 29786922
J Psychopharmacol. 2023 Mar;37(3):268-278
pubmed: 35861202
Psychiatry Res. 2023 Sep;327:115378
pubmed: 37574600
Am J Psychiatry. 2019 Jun 1;176(6):428-438
pubmed: 31109201